PharmaResources(Shanghai) Co., Ltd. is a rapidly developing new drug R & D service and API manufacturer. Since its establishment in December 2007, the company has been actively cooperating with customers and business partners to become a leading enterprise in the research, production and sales of new drug creation services and API process innovation with the driving force of scientific and technological innovation and the goal of creating a distinctive "intelligent" innovation enterprise.
PharmaResources(Shanghai) Co., Ltd. headquarter is located in the east of Zhangjiang hi tech Industrial Park, Pudong New Area, Shanghai, with nearly 8000 square meters of office area, laboratory and advanced equipment. Since its inception, the company has strived to create a safe, comfortable and scientific working environment for its employees. At present, the company has NMR (Bruker 400m), SFC, HPLC, chinese-hplc, LC-MS, LC-MS / MS (API 4000), IR, UV, GC, GC-MS, positive / reverse phase preparative chromatography, microwave synthesizer, parallel synthesizer and other experimental and testing equipment. It is such a high-quality research environment that ensures the high-quality operation and research results of PharmaResources pharmaceutical research and development department. As a high-tech enterprise, the company has so far applied for 44 invention patents (including 5 PCTs), 22 authorized patents and 44 applied patents.
PharmaResources(Kaiyuan) Co., Ltd. located in Kaiyuan city, Liaoning Province, as a production base, covers an area of 150000 square meters. It has plants, equipment facilities and inspection systems that meet the current GMP standards. It is mainly engaged in the research, development, production and sales of high-end chemical APIs and intermediates at the international forefront. The existing products include tegrilo Palamiway, vipatavi, sofibwe, etc. have obtained EU cos certificate and a number of international high-end certificates. Meanwhile, they have long-term cooperation with many foreign well-known enterprises, such as Pfizer, Abbott in the United States, Novartis in Switzerland, Sanofi in France, chemo in Italy, Teva in Israel, Dr Reddy in India, Cipla, etc., which has great potential for rapid development.
At present, the company has nearly 300 employees, of which about 10% are doctors (50% of them have overseas study or work experience), 25% are masters and 55% are bachelors. In 2010, the company was rated as an advanced technology service enterprise, and from 2014 to 2017, the company was successively rated as a high-tech enterprise. Dr. Chen Ping and Dr. Cai Zhenwei, senior vice president of pharmaceutical chemistry, are senior experts in pharmaceutical chemistry. They won the Thomas Edison new drug invention patent award in 2008 and 2011 respectively for their outstanding contributions to a class of new anti-cancer drugs.
PharmaResources(Shanghai) Co., Ltd. attaches great importance to building a "science oriented, continuous innovation" corporate culture, and infiltrates it into the company's management system, talent training, team building and other aspects. In addition to focusing on the cultivation of scientific and experimental operation ability, the company organizes annual meeting, quality development training, group tourism, birthday party and various cultural and sports activities every year, and also sets up a special fund for team building. These activities not only provide vertical and horizontal communication opportunities for employees, but also enhance their sense of belonging and team cooperation.
On April 25, 2016, PharmaResources(Shanghai) Co., Ltd. formally passed the examination and approval of the listing of shares in the national small and medium-sized enterprise stock transfer system (the new third board) (hereinafter referred to as PharmaResources pharmaceutical; Stock Code: 837359). At the end of 2017, the company launched an equity incentive plan to motivate and retain talents, which greatly improved and encouraged the morale of employees and encouraged everyone to grow and develop together with the company.